About Jimena Vicencio

Articles by Jimena Vicencio, MD

What Does Erythrocytosis Mean?
Jul 03, 2024
Celebrating Two Decades with Multiple Myeloma: Vicki Jones’ Journey
Jun 24, 2024
ASCO 2024: BCMA-Directed Therapies in Relapsed Multiple Myeloma
Jun 24, 2024
Luspatercept Can Improve Anemia and Reduce Transfusion Dependency in MDS
Jun 23, 2024
What Is The Difference Between Chronic And Acute Leukemia?
Jun 21, 2024
ASCO 2024: What’s the Right Dose of Azacitidine for Low- and Intermediate-Risk MDS Patients?
Jun 20, 2024
What is Early Primary Myelofibrosis?
Jun 18, 2024
HealthTree Research Results: The Role of Dietary Supplements in Cancer Patient Care
Jun 17, 2024
Do MRD-Negative Patients Still Benefit From Transplant?
Jun 17, 2024
ASCO 2024: New Hope for Newly Diagnosed Multiple Myeloma Patients
Jun 12, 2024
ASCO 2024: The MANIFEST-2 Study for Myelofibrosis
Jun 12, 2024
Can MPNs Progress to Leukemia?
Jun 06, 2024
What is Translocation t(14;18) in Follicular Lymphoma?
Jun 03, 2024
Does Screening for MGUS Bring Psychological Benefits? Insights from the iStopMM Study
Jun 03, 2024
Updated Recommendations for Oral Azacitidine to Maintain Longer AML Remissions
May 13, 2024
Gaps in MDS Patient Knowledge Revealed by Cancer Experience Registry® Study
May 13, 2024
Study of Evorpacept and Azacitidine for High-Risk MDS
May 07, 2024
$Evorpacept - A Next-Generation CD47 Inhibitor in Phase I Study for Patients With Relapsed-Refractory Lymphoma image$

Evorpacept - A Next-Generation CD47 Inhibitor in Phase I Study for Patients With Relapsed-Refractory Lymphoma
May 06, 2024
BMI Shouldn’t Be a Barrier for Transplant Eligibility
May 01, 2024
Can AI Detect MGUS Progression With Our Fat Cells?
Apr 30, 2024
From Diagnosis to Relapse: Mapping the Course of MDS After Allo-HSCT
Apr 29, 2024
How Does MDS Progress to AML?
Apr 29, 2024
What To Eat if You Have Myelofibrosis?
Apr 29, 2024
A New Drug for MDS: Elritercept (KER-050)
Apr 24, 2024